wanted to re-read the PR and sleep on it / think about this
wanted to re-read the PR and sleep on it / think about this a bit more. first off - i'm glad Cyrus is ok. i still maintain this was stress related - but that's his business and i don't really need to know, and i am glad he is alright as he seems like a good guy.
in terms of the PR, my gut is that this is definitely not the PR they wanted to put out. they waited the better part of 2 months to announce........pretty much nothing. we already knew about the lawsuit, but they're announcing that they requested a hearing date, which is just a procedural thing.
- and Cyrus' "return" could be 2 hours / week for all we know - in fact, they went to great lengths to stress the "reduced hours". Tanya said he will "lend his expertise" - to me that means he will have no active role in running the company, which is clear in Antonio having the only comments with regard to the direction of the company in the PR. I think Cyrus / The Company agreed to this reduced role to show some continuity because they had hoped to have identified a CEO by the time of the next call, but either weren't able to, or something fell through - and they couldn't wait any longer to communicate. Otherwise there is no way they wait over 6 weeks to simply announce a call (that won't happen for another 2 weeks). and the fact that there is no mention of the hold suggests they haven't responded to the FDA yet - which i'm not surprised about given these recent developments.
not trying to be a debbie downer, but that's just how i see it. someone posted that we need a buyout or some other partnership to have someone else pick up the ball and get this drug to market. amen to that. we're all here because we believe in Leronlimab - but good lord, i have never seen such a train-wreck in terms of the actual "business" side of things in all my years of investing.
i'll end on a positive note - they put the call 2 weeks out. i'm hoping it's because they expect to have something in the bag by then - new CEO, or the submission of the materials, etc.
8
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...
Continue Reading
A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....
Continue Reading
A Crowded Singapore Room Says Something Singapore did not host a mere anniversary toast on November 18; it hosted a pretty revealing cross-section of the businesses trying to build, secure, cool, connect, finance, and digitize Asia Pacific and MEASA. Frost & Sullivan marked 65 years with its 2026 Best Practices Recognition banquet at Hilton Singapore Orchard, gathering...
Continue Reading
Anthropic shares have landed on Bybit Stocks, and the headline is simple enough: eligible customers can trade ANT after the company’s public listing. But this is one of those announcements where the plumbing deserves as much attention as the shiny new ticker. A platform can make access feel effortless right up until a jurisdiction rule, a verification hurdle, or a...
Continue Reading
When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...
Continue Reading
A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...
Continue Reading
Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...
Continue Reading
Buried beneath the usual utility-company polish is a pretty sensible idea: find waste before a customer gets walloped by a bill. SoCalGas says its Advanced Meter Analytics program has helped customers avoid an estimated $11 million in unnecessary natural-gas costs since 2019. That is not a number likely to move Sempra’s earnings by itself, and nobody should pretend...
Continue Reading
A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...
Continue Reading
A Refinancing With Some Actual Breathing Room Metal cans may be boring, but a debt wall arriving in 2028 is not—and Ardagh Metal Packaging has moved that problem down the road. AMP priced €1.3 billion of senior secured floating-rate green notes on November 20, 2026. The proceeds are earmarked to redeem $600 million of senior secured green notes due in 2028 and €450...
Continue Reading
Top 5 Most Recently Viewed Articles
Overview of the Flat Glass Market The flat glass market is on a remarkable trajectory, currently valued at USD 179.80 billion and poised to soar to USD 280.64 billion in the next few years, reflecting a compound annual growth rate (CAGR) of 8.0%. This growth is predominantly fueled by the booming construction and automotive sectors, coupled with a rising demand for...
Continue Reading
Celebrating a Milestone for the Everglades Foundation The Everglades Foundation has achieved a monumental success, surpassing its fundraising target during its inaugural endowment campaign. With a remarkable outpouring of support, the Foundation raised $76 million in gifts and pledges from a dedicated group of 80 donors. This significant achievement ensures the long-term...
Continue Reading
Understanding Government's Generative AI Landscape Government agencies are expressing considerable optimism about the potential of Generative AI (GenAI) technology, even as they face challenges in its implementation. Recent insights highlight that while budgeting for these innovations is high, the actual deployment of GenAI remains behind other industries. Survey findings...
Continue Reading
Your Rights as a DXC Technology Investor If you're an investor in DXC Technology Company (NYSE: DXC), it’s important to understand your rights and the ongoing legal issues that could impact you. Bernstein Liebhard LLP, a well-respected law firm, wants to remind all DXC shareholders of a critical deadline that’s approaching. Who Needs to Be Concerned? Do you own shares...
Continue Reading
Business Update and Financial Highlights LM Funding America, Inc. (NASDAQ: LMFA) has recently shared its financial results for the third quarter of 2024. This Tampa-based company focuses on cryptocurrency mining and technological finance solutions, showcasing significant strategic developments in its operations. Bitcoin Holdings and Revenue Performance As of September 30,...
Continue Reading